glp-1 news today 2025-10-16 trends 2025: real-world data, patient outcomes & future therapies Alarming rise in weight loss

Data were analyzed narratively to elucidate potential mechanisms and translational relevance

These revelations indicate an expanded therapeutic scope for GLP-1RA, surpassing its conventional application in the management of diabetes

GLP-1R agonist 2 (100 nM, 1,000 nM) promotes glucose-dependent insulin secretion in CD1 mouse islets, and this effect is dependent on the GLP-1 receptor

Sources Ozempic- semaglutide injection, solution [package insert]

Theme 3: reduced appetite and increased control of eating behaviours The most consistent theme emerging from the interviews was changes in eating behaviours

21 Several incretin-based therapies, including liraglutide, dulaglutide, semaglutide, and tirzepatide, are currently approved for patients with type 2 diabetes ( Table )